Methylphenidate "hexal" (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine at neuronal synapses, raising their levels in the brain. The increased catecholamine activity enhances signaling in pathways that regulate attention, impulse control, and arousal, which underlies its therapeutic effect in ADHD and narcolepsy.

The appropriate dose of Methylphenidate is individualized by the prescribing clinician based on factors such as age, weight, severity of symptoms, and response to therapy. No fixed regimen can be stated; the prescriber adjusts the dose to achieve optimal benefit while minimizing side effects.

Safety data for Methylphenidate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and discuss alternative options with patients who are pregnant or nursing.

To request Methylphenidate "hexal", submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate belongs to the central nervous system stimulant class and is often compared with amphetamine‑based agents. Both increase dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake, whereas amphetamines also promote release. Choice of therapy depends on individual response, side‑effect profile, and clinician preference.

Methylphenidate "hexal" tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Methylphenidate "hexal" is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, according to the prescribing physician’s instructions. Doses are usually divided throughout the day to maintain steady symptom control.

Serious risks include cardiovascular events such as hypertension, chest pain, or arrhythmias, and psychiatric effects like severe anxiety, hallucinations, or manic episodes. Monitoring for these conditions is essential, especially in patients with pre‑existing heart disease or mental health disorders.

Methylphenidate is contraindicated in individuals with severe hypertension, known hypersensitivity to the drug, or those currently taking monoamine oxidase inhibitors (MAOIs). It should also be avoided in patients with certain cardiac conditions, uncontrolled anxiety disorders, or a history of substance misuse without careful medical supervision.